antibacterial agent 31

Antibacterial agent 31 exhibits (shows) efficacy (activity) in combating (against) rice bacterial leaf streak.

Antibacterialagent 313 (Compound 20) is a broad-spectrum antibacterial agent. It demonstrates potent inhibitory effects against Gram-positive bacteria, with a minimum inhibitory concentration (MIC) of 0.125 μg/mL for Staphylococcus aureus (ATCC 29213) and MIC values between 0.125-0.5 μg/mL for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus aureus (VRSA) clinical isolates. Additionally, Antibacterialagent 313 also shows inhibitory activity against certain Gram-negative bacteria, such as Escherichia coli (ATCC 25922), with an MIC of 3.03 μg/mL. The compound exhibits low cytotoxicity to CHO-K1 cells, with an IC50 value of 9 μg/mL, making it a useful candidate for bacterial infection research.

Antibacterialagent 310 (compound 2) is a chelating ligand derived from dibenzimidazole, exhibiting antibacterial activity. It also shows inhibitory effects on intracellular viruses and can be utilized in antibacterial research.

Antibacterialagent 311 (Compound 4f) is an antibacterial agent that exhibits activity against Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, E. CTXM1, and E. NDM1, with minimum inhibitory concentrations (MIC) of 0.8, 1, 1, 1, 0.7, and 0.7 mg/mL, respectively.

LP07 is an antibacterial agent targeting Pseudomonas aeruginosa. It exhibits a minimum inhibitory concentration (MIC) of 8 μg/mL against both wild-type and efflux pump-deficient strains of P. aeruginosa PA14. LP07 exerts its antibacterial effects by directly disrupting the structural integrity of bacterial cell membranes. It shows moderate inhibition of MMP-17 and MMP-19 but has no significant inhibitory effect on other MMP subtypes. LP07 does not inhibit LpxC enzyme activity and can be utilized in research on Pseudomonas aeruginosa infections.

Antibacterialagent 317 (Compound 5h) is an antibacterial agent with various mechanisms of action. These include enhancing cell membrane permeability, inhibiting the production of exopolysaccharides and cell membrane formation, and disrupting the biosynthesis of flagella and methionine. It effectively suppresses the growth of the plant pathogens Xanthomonas oryzae pv. oryzicola (Xoc) and Xanthomonas oryzae pv. oryzae (Xoo), with EC50 values of 1.53 and 6.07 μg/mL, respectively.

Antibacterialagent 316 (Compound C1-15) is an antibacterial agent. It exhibits antibacterial activity against Xanthomonas oryzae pv oryzae, Xanthomonas axonopodis pv citri, and Pseudomonas solanacearum, with a MIC range of 1.56 to 6.25 μg/mL. Additionally, Antibacterialagent 316 shows antifungal activity against Rhizoctonia solani and Botrytis cinerea.

Antibacterialagent 312 (Compound 8c) is a potent antibacterial agent that effectively disrupts the integrity of bacterial inner membranes, increasing membrane permeability. Its minimum inhibitory concentrations (MIC) against Vibrio parahaemolyticus and Vibrio alginolyticus are 6 and 16 μg/mL, respectively. Antibacterialagent 312 exhibits bactericidal activity against Vibrio parahaemolyticus and effectively inhibits biofilm formation. It demonstrates excellent biosafety, making it suitable for studying infections caused by the aquaculture pathogen Vibrio parahaemolyticus.

Arcopilin A (compound Arcopilin A(1)) functions as an antibacterial agent with moderate inhibitory capabilities against fungal pathogens and Gram-positive bacteria, exhibiting IC 50 values of 8.9 μg/mL for KB-3-1 cells and 14 μg/mL for L929 cells. Notably, it can effectively eradicate preformed biofilms of Staphylococcus aureus. Additionally, Arcopilin A significantly boosts the efficacy of gentamicin (GM) and vancomycin (Vac), enhancing their activities by 115 and 31 times, respectively.

Antimicrobial agent-31 (compound 4a) is a potent antibacterial compound. It exhibits minimum inhibitory concentrations (MIC) of 19.24 µg/mL against Salmonella enterica serovar Typhimurium and 11.31 µg/mL against E. coli.

Anti-MRSA agent 31 (Compound 6) is an agent effective against methicillin-resistant Staphylococcus aureus (MRSA), with a minimum inhibitory concentration (MIC) of 97 μg/mL and a minimum bactericidal concentration (MBC) of 781.25 μg/mL. It exhibits potent antibacterial activity and significant inhibitory action on penicillin-binding protein 2a (PBP2a).